openPR Logo
Press release

Investigation announced for Investors in NYSE: SQZ shares over possible Wrongdoing at SQZ Biotechnologies Company

02-18-2023 04:00 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in SQZ Biotechnologies Company (NYSE: SQZ) shares over potential wrongdoing.

An investigation on behalf of investors in SQZ Biotechnologies Company (NYSE: SQZ) shares over potential wrongdoing.

An investigation was announced over possible breaches of fiduciary duties by certain directors at SQZ Biotechnologies Company.

Investors who purchased shares of SQZ Biotechnologies Company (NYSE: SQZ) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain SQZ Biotechnologies directors breached their fiduciary duties and caused damage to the company and its shareholders.

Watertown, MA based SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. SQZ Biotechnologies Company reported that its annual Total Revenue rose from $20.99 million in 2020 to $27.09 million in 2021, and that its Net Loss increased from $50.52 million in 2020 to $68.74 million in 2021.

On or around October 29, 2022, SQZ Biotechnologies Company conducted its initial public offering ("IPO"), selling 4,411,765 shares priced at $16.00 per share.

Then, on December 1, 2022, SQZ Biotechnologies Company issued a press release "announc[ing] that Armon Sharei, PhD, Chief Executive Officer at SQZ Biotechnologies, will step down from his role as CEO and the Board of Directors, effective immediately," and that the Company will reduce its workforce by roughly 60% as it "pause[s] its APC, Activating Antigen Carrier (AAC) and Tolerizing Antigen Carrier (TAC) programs."

Shares of SQZ Biotechnologies Company (NYSE: SQZ) declined to as low as $1.41 per share on December 5, 2022.

Those who purchased shares of SQZ Biotechnologies Company (NYSE: SQZ) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in NYSE: SQZ shares over possible Wrongdoing at SQZ Biotechnologies Company here

News-ID: 2936970 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for SQZ

Human Papillomavirus Associated Cancer Pipeline 2025: Therapies, MOA Insights, a …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Human Papillomavirus Associated Cancer pipeline constitutes key companies continuously working towards developing Human Papillomavirus Associated Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Human Papillomavirus Associated Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Human
Human papillomavirus Associated Cancer Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Human papillomavirus (HPV) Associated Cancer Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Human
Type 1 Diabetes Drugs Analysis, (2023 Updates): Clinical Trials, Treatment Thera …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Type 1 Diabetes pipeline constitutes 80+ key companies continuously working towards developing 100+ Type 1 Diabetes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Type 1 Diabetes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also
Human papillomavirus (HPV) Associated Cancer Pipeline Analysis Demonstrates Nove …
DelveInsight's, "Human papillomavirus (HPV) Associated Cancer Pipeline Insight, 2023," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Human papillomavirus (HPV) Associated Cancer pipeline landscape. It covers the Human papillomavirus (HPV) Associated Cancer pipeline drug profiles, including Human papillomavirus (HPV) Associated Cancer clinical trials and nonclinical stage products. It also covers the Human papillomavirus (HPV) Associated Cancer pipeline therapeutics assessment by product type, stage, route of administration,
Investigation announced for Investors in shares of SQZ Biotechnologies Company ( …
An investigation was announced for investors of SQZ Biotechnologies Company (NYSE: SQZ) shares over potential securities laws violations by SQZ Biotechnologies Company. Investors who purchased shares of SQZ Biotechnologies Company (NYSE: SQZ), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of SQZ Biotechnologies Company (NYSE: SQZ)
The Type 1 Diabetes Market Size is anticipated to increase during the study peri …
With the expected launch of emerging therapies, the Type 1 Diabetes market is expected to show positive growth in the forecast period in the 7MM. Moreover, increased awareness of Type 1 Diabetes has amplified drug research and development. The Type 1 Diabetes market report provides current treatment practices, emerging drugs, Type 1 Diabetes market share of the individual therapies, current and forecasted Type 1 Diabetes Market Size from 2019 to